MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Marker Therapeutics ROE Ratio 2011-2026 | MRKR
Annual ROE Ratio Marker Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -72.42 | -57.82 | -58.61 | -152.7 | -95.21 | -104.98 | -48.6 | -249.34 | -300.21 | -39.7 | 159.48 | 3017.0 | 63.1 | 103.38 | 58.63 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3017.0 | -300.21 | 148.13 |
Quarterly ROE Ratio Marker Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -110.81 | -130.93 | -115.25 | -73.88 | -91.73 | -78.59 | -42.78 | -35.85 | -66.46 | -79.23 | -125.43 | -91.36 | -115.13 | -108.29 | -92.55 | -53.13 | -80.09 | -83.27 | -89.22 | -73.87 | -86.25 | -71.68 | -61.12 | -37.08 | -44.48 | -39.49 | -34.97 | -20.89 | -129.84 | -231.4 | -275.04 | -226.86 | -260.86 | -185.92 | -37.56 | -14.21 | -147.65 | -247.08 | -61.77 | 151.75 | 304.91 | 591.51 | 236.0 | 2981.68 | 3005.14 | 2875.44 | 2958.98 | 1004.35 | 1004.35 | 1022.98 | 1055.14 | 94.08 | 76.39 | 100.79 | 70.39 | 72.72 | 24.4 | 11.69 | 36.63 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3005.14 | -275.04 | 232.67 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
-55.54 | $ 209.63 | -0.71 % | $ 371 B | USA |
 |
Verastem
VSTM
|
-366.23 | $ 4.99 | -5.77 % | $ 346 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-73.05 | $ 0.57 | -5.85 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Voyager Therapeutics
VYGR
|
-61.06 | $ 3.96 | -4.24 % | $ 232 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-27.19 | $ 12.36 | -11.46 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-39.43 | $ 6.39 | 3.06 % | $ 1.08 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
-36.25 | $ 2.78 | -0.71 % | $ 4.73 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
XBiotech
XBIT
|
-32.45 | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-31.04 | $ 54.44 | -1.96 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
4.05 | $ 5.41 | -2.87 % | $ 868 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
-42.51 | $ 4.07 | -5.57 % | $ 172 M | USA |
 |
Xencor
XNCR
|
-14.46 | $ 11.4 | -7.43 % | $ 846 M | USA |
 |
XOMA Corporation
XOMA
|
37.78 | $ 29.93 | -1.97 % | $ 362 M | USA |
 |
22nd Century Group
XXII
|
-32.07 | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-207.61 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-63.65 | $ 1.06 | -2.75 % | $ 21.7 M | Israel |
 |
Enochian Biosciences
ENOB
|
833.76 | - | - | $ 40.5 M | USA |